Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) – a study protocol
| Autor: | Sebastiaan T. Houweling, Dennis Schrijnders, Jeffrey A. Johnson, Klaas H. Groenier, Kornelis J. J. van Hateren, Nanne Kleefstra, Henk J. G. Bilo, Geertruida H. de Bock, Gijs W. D. Landman |
|---|---|
| Přispěvatelé: | Damage and Repair in Cancer Development and Cancer Treatment (DARE), Life Course Epidemiology (LCE), Lifestyle Medicine (LM), Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE) |
| Rok vydání: | 2017 |
| Předmět: |
Male
Oncology Cancer Research BLOOD-PRESSURE Study Protocol 0302 clinical medicine Risk Factors Neoplasms Epidemiology of cancer Sulfonylureas 030212 general & internal medicine Prospective cohort study Netherlands Cancer education.field_of_study Type 2 diabetes ASSOCIATION lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Cohort PIOGLITAZONE Female Cohort study medicine.medical_specialty METFORMIN Population Within-class differences BLADDER-CANCER 030209 endocrinology & metabolism lcsh:RC254-282 03 medical and health sciences Internal medicine Genetics medicine Humans DRUGS COHORT Obesity Lung cancer education METAANALYSIS Proportional Hazards Models Gynecology Bladder cancer business.industry MORTALITY medicine.disease BODY-MASS INDEX Sulfonylurea Compounds Diabetes Mellitus Type 2 Quality of Life business |
| Zdroj: | BMC Cancer, 17:444. BMC BMC Cancer, Vol 17, Iss 1, Pp 1-5 (2017) BMC Cancer |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-017-3433-z |
| Popis: | Background Patients with type 2 diabetes (T2D) are at increased risk for developing cancer. As approximately 8% of the world’s population is living with T2D, even a slight increase in cancer risk could result in an enormous impact on the number of persons developing cancer. In addition, several glucose lowering drug classes for treating patients with T2D have been associated with a difference in risk of cancer overall, and especially for obesity related cancers. In what way and to what degree cancer risk is modified by the use of different sulfonylureas (SU) is unclear. The primary aim of this study will be to evaluate within-class SU differences in obesity related cancer risk. Secondary aims will be to investigate within-class SU differences in risk for all cancers combined and site-specific cancers separately (i.e. breast, colorectal, prostate, bladder and lung cancer) and to account for duration-response relationships between individual SU use and cancer risk. Methods Patients will be selected from a Dutch primary care cohort of patients with T2D linked with the Dutch Cancer Registration (ZODIAC-NCR). Within this cohort study annually collected clinical data (e.g. blood pressure, weight, HbA1c) and nationwide data on cancer incidence are available. Time-dependent cox proportional hazard analyses will be performed to evaluate SU cancer risk, adjusted for potential confounders. Discussion This study will be the first prospective cohort study investigating within-class SU differences in cancer risk and could contribute to improved decision making regarding the individual drugs within the class of SUs, and possibly improve quality of life and result in an increased cost-effectiveness of healthcare in patients with T2D. Trial registration Nederlands Trialregister ( NTR6166 ), 6 Jan 2017. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|